kneat.com (TSE:KSI) Reaches New 12-Month High – Still a Buy?

kneat.com, inc. (TSE:KSI) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as C$6.87 and last traded at C$6.84, with a volume of 166540 shares trading hands. The stock had previously closed at C$6.57.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on KSI shares. CIBC set a C$6.00 price target on shares of kneat.com and gave the company an “outperform” rating in a research report on Tuesday, October 29th. Cibc World Mkts raised shares of kneat.com to a “strong-buy” rating in a report on Tuesday, October 29th.

kneat.com Stock Up 4.1 %

The company has a current ratio of 1.47, a quick ratio of 1.50 and a debt-to-equity ratio of 95.14. The stock has a market capitalization of C$588.24 million, a PE ratio of -42.75, a P/E/G ratio of 597.67 and a beta of 1.08. The stock’s fifty day simple moving average is C$6.06 and its 200-day simple moving average is C$5.22.

kneat.com (TSE:KSI) last released its earnings results on Wednesday, November 6th. The company reported C$0.01 EPS for the quarter, topping analysts’ consensus estimates of C($0.05) by C$0.06. kneat.com had a negative return on equity of 51.13% and a negative net margin of 31.19%. During the same quarter in the previous year, the business posted ($0.05) EPS. As a group, sell-side analysts forecast that kneat.com, inc. will post -0.12 EPS for the current fiscal year.

About kneat.com

kneat.com, inc., together with its subsidiaries, designs, develops, and supplies software for data and document management within regulated environments in North America, Europe, and the Asia Pacific. The company offers the Kneat Gx platform, a configurable off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries.